Novel Strategies to Identify and Eliminate Latent HIV Cells
A special issue of Viruses (ISSN 1999-4915). This special issue belongs to the section "Human Virology and Viral Diseases".
Deadline for manuscript submissions: 31 December 2024 | Viewed by 465
Special Issue Editor
Interests: HIV; HIV reservoir; quantification of HIV DNA and RNA; single cells analysis; HIV reactivation; HIV cure; HIV vaccines
Special Issue Information
Dear Colleagues,
Due to the availability of antiretroviral therapy (ART), HIV-1 infection has transitioned into a chronic condition. ART effectively suppresses plasma viral loads to undetectable levels, thereby preventing the progression to AIDS. However, the virus remains latent and persists in the body, posing a significant challenge to achieving a cure. If ART is discontinued, the virus rebounds, necessitating lifelong medication for those affected.
Cutting-edge technologies have dramatically enhanced our understanding of HIV-1 infection at the single-cell level (for example, HIVseq, FINDseq, viral ASAPseq), facilitating remarkable progress in the field.
Despite numerous setbacks in the quest for a cure, novel therapeutic approaches have already reached the clinical trial stage, and new strategies are continually being proposed and implemented (for example CRISPR, targeted lipid nanoparticles, broadly neutralizing antibodies, AZD5582, trimeric Env, TLR7 agonist, anti-HIV CAR-T and/or a combination of them).
The objective of this Special Issue of Viruses is to examine and discuss recent advancements in the analysis of HIV-1 viral infection at the single-cell level, as well as the latest ongoing efforts in developing new cure strategies.
Dr. Francesco Andrea Procopio
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- HIV
- HIV-1 infection
- antiretroviral therapy (ART)
-
HIV single cell analysis
- HIV reservoir
- HIV cure
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
